Emerging Immunotargets and Immunotherapies in Prostate Cancer

Author(s): Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Rossana Berardi, Marina Scarpelli

Journal Name: Current Drug Targets

Volume 17 , Issue 7 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.

Keywords: Immunotherapy, programmed death-1, prognosis, prostate cancer, vaccines.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [777 - 782]
Pages: 6
DOI: 10.2174/1389450117666160217123304
Price: $65

Article Metrics

PDF: 54
PRC: 1